Biology and management of inflammatory breast cancer

References

• Lee BJ, Tannenbaum EN. Inflammatory carcinoma of the breast. Surg. Gynecol. Obstet.39, 580–595 (1924).
   Google Scholar
• Levine PH, Steinhorn SC, Ries LG, Aron JL. Inflammatory breast cancer: the experience of the Surveillance, Epidemiology, and End Results (SEER) program. J. Natl Cancer Inst.74(2), 291–297 (1985).
   PubMed Web of Science ®Google Scholar
• Green FL, Page DL, Fleming ID et al. Breast. In: AAJCC Cancer Staging Manual (6th edition). Springer-Verlag, NY, USA 225–281 (2002).
   Google Scholar
• Bozzetti F, Saccozzi R, De Lena M et al. Inflammatory cancer of the breast: analysis of 114 cases. J. Surg. Oncol.18(4), 355–361 (1981).
   PubMedGoogle Scholar
• Barker JL, Nelson AJ, Montague ED. Inflammatory carcinoma of the breast. Radiology121(1), 173–176 (1976).
   PubMed Web of Science ®Google Scholar
• Zucali R, Uslenghi C, Kenda R et al. Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy. Cancer37(3), 1422–1431 (1976).
   PubMed Web of Science ®Google Scholar
• Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results program at the National Cancer Institute. J. Natl Cancer Inst.97(13), 966–975 (2005).
   PubMed Web of Science ®Google Scholar
• Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD. Inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results program of the National Cancer Institute, 1975–1992. Cancer82(12), 2366–2372 (1998).
   PubMed Web of Science ®Google Scholar
• Wingo PA, Jaminson PM, Young JL, Gargiullo P. Population-based statistics for women diagnosed with inflammatory breast cancer (United States). Cancer Causes Control15(3), 321–328 (2004).
   PubMedGoogle Scholar
• Chang S, Buzdar AU, Hursting SD. Inflammatory breast cancer and body mass index. J. Clin. Oncol.16(12), 3731–3735 (1998).
   Google Scholar
• Mourali N, Muenz LR, Tabbane F et al. Epidemiological features of rapidly progressing breast cancer in Tunisia. Cancer46(12), 2741–2746 (1980).
   PubMed Web of Science ®Google Scholar
• Maalej M, Frikha H, Ben Salem S et al. Breast cancer in Tunisia: clinical and epidemiological study. Bull. Cancer86(3), 302–306 (1999).
   Google Scholar
• Levine PH, Pogo BG, Coronel S et al. Increasing evidence for a human breast cancer virus with geographic differences. Cancer101(4), 721–726 (2004).
   PubMed Web of Science ®Google Scholar
• Shiramizu B, Barriga F, Neequaye J et al. Patterns of chromosomal breakpoint locations in Burkitt’s lymphoma: relevance to geography and Epstein–Barr virus association. Blood77(7), 1516–1526 (1991).
   PubMed Web of Science ®Google Scholar
• Taylor G, Meltzer A. Inflammatory carcinoma of the breast. Am. J. Cancer33, 33–49 (1938).
   Google Scholar
• Haagensen CD. Inflammatory carcinoma. In: Diseases of the Breast. WB Saunders, PA, USA, 488–498 (1956).
   Google Scholar
• Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J. Clin. Oncol.10(6), 1014–1024 (1992).
   PubMed Web of Science ®Google Scholar
• Kim T, Lau J, Erban J. Lack of uniform diagnostic criteria for inflammatory breast cancer limits interpretation of treatment outcomes: a systematic review. Clin. Breast Cancer5(5), 386–395 (2006).
   Google Scholar
• Attia-Sobol J, Ferrière JP, Curé H, Kwiatkowski F et al. Treatment results, survival and prognostic factors in 109 inflammatory breast cancers: univariate and multivariate analysis. Eur. J. Cancer29(8), 1081–1088 (1993).
   Google Scholar
• Kleer CG, van Golen KL, Merajver SD. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res.2(6), 423–429 (2000).
   PubMed Web of Science ®Google Scholar
• Delarue JC, May-Levin F, Mouriesse H et al. Oestrogen and progesterone cytosolic receptors in clinically inflammatory tumors of the human breast. Br. J. Cancer44(6), 911–916 (1981).
   Google Scholar
• Bonnier P, Charpin C, Lejeune C et al. Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition? Int. J. Cancer62(4), 382–385 (1995).
   PubMed Web of Science ®Google Scholar
• Jardines L, Haffty BG, Theriault RL. Locally advanced, locally recurrent and metastatic breast cancer. In: Cancer Management. A Multidisciplinary Approach (3rd edition). Pazdur R, Coia LR, Hoskins WJ, Wagman LD (Eds). Melville, NY, USA, 73–88 (1999)
   Google Scholar
• Harvey HA, Lipton A, Lawrence BV et al. Estrogen receptor status in inflammatory breast carcinoma. J. Surg. Oncol.21(1), 42–44 (1982).
   PubMed Web of Science ®Google Scholar
• Nguyen DM, Sam K, Tsimelzon A et al. Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin. Cancer Res.12(17), 5047–5054 (2006).
   PubMed Web of Science ®Google Scholar
• Guerin M, Gabillot M, Mathieu MC et al. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int. J. Cancer43(2), 201–208 (1989).
   PubMedGoogle Scholar
• Guerin M, Sheng ZM, Andrieu N et al. Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene5(1), 131–135 (1990).
   PubMed Web of Science ®Google Scholar
• Parton M, Dowsett M, Ashley S et al. High incidence of HER-2 positivity in inflammatory breast cancer. Breast13(2), 97–103 (2004).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science235(4785), 177–182 (1987).
   PubMed Web of Science ®Google Scholar
• Dawood S, Broglio K, Gong Y et al. Inflammatory Breast Cancer Research Group. Prognostic significance of HER-2 status in women with inflammatory breast cancer. Cancer112(9), 1905–1911 (2008).
   PubMed Web of Science ®Google Scholar
• Yonish-Rouach E, Resnitzky D, Lotem J et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature352(6333), 345–347 (1991).
   PubMed Web of Science ®Google Scholar
• Aas T, Borresen AL, Geisler S et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med.2(7), 811–814 (1996).
   PubMed Web of Science ®Google Scholar
• Feki A, Irminger-Finger I. Muational spectrum of p53 mutations in primary breast and ovarian tumors. Crit. Rev. Oncol. Hematol.52(2), 103–116 (2004).
   PubMed Web of Science ®Google Scholar
• Angulo-Gonzalez AM, Sneige N, Kau SW et al. p53 expression as a prognostic marker in inflammatory breast cancer. Clin. Cancer Res.10(18), 6215–6221 (2004).
   Google Scholar
• Riou G, Lê MG, Travagli JP, Levine AJ, Moll UM. Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J. Natl Cancer Inst.85(21), 1765–1767 (1993).
   Google Scholar
• Gamallo C, Palacios J, Suarez A et al. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am. J. Pathol.142(4), 987–993 (1993).
   PubMed Web of Science ®Google Scholar
• Oka H, Shiozaki H, Kobayashi K et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res.53, 1696–1701 (1993).
   PubMed Web of Science ®Google Scholar
• Alpaugh ML, Tomlinson JS, Shao ZM et al. A novel human xenograft model of inflammatory breast cancer. Cancer Res.59(20), 5079–5084 (1999).
   PubMedGoogle Scholar
• Tomlinson JS, Alpaugh MK, Barsky SH. An intact overexpressed E-cadherin/a, β-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res.61(13), 5231–5241 (2001).
   PubMedGoogle Scholar
• Hoffmeyer MR, Wall KM, Dharmawardhane SF. In vitro analysis of the invasive phenotype of SUM 149, an inflammatory breast cancer cell line. Cancer Cell Int.5(1), 11 (2005).
   PubMedGoogle Scholar
• Kleer CG, van Golen KL, Braun T et al. Persistent E-cadherin expression in inflammatory breast cancer. Mod. Pathol.14(5), 458–464 (2001).
   Google Scholar
• Van der Auwera I, Van Laere SJ, Van Den Eynden GG et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin. Cancer Res.10(23), 7965–7971 (2004).
   PubMed Web of Science ®Google Scholar
• Weidner N, Folkman J, Pozza F et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl Cancer Inst.84(24), 1875–1887 (1992).
   PubMed Web of Science ®Google Scholar
• Colpaert CG, Vermeulen PB, Benoy I et al. Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br. J. Cancer88(5), 718–725 (2003).
   Google Scholar
• Gonzalez-Angulo AM, Guarneri V, Gong Y et al. Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer. Clin. Breast Cancer7, 326–330 (2006).
   Google Scholar
• Cabioglu N, Gong Y, Islam R et al. Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann. Oncol.18(4), 1021–1029 (2007).
   PubMed Web of Science ®Google Scholar
• Gong Y, Gonzalez-Angulo Am, Broglio K et al. Expression of Notch-1 and B-catenin: defining the molecular portrait of inflammatory breast cancer. Breast Cancer Res. Treat.100, S299 (2006).
   Google Scholar
• van Golen KL, Wu ZF, Qiao XT et al. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res.60(20), 5832–5838 (2000).
   PubMed Web of Science ®Google Scholar
• van Golen KL, Davies S, Wu ZF et al. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin. Cancer Res.5(9), 2511–2519 (1999).
   PubMed Web of Science ®Google Scholar
• Kleer CG, Griffith KA, Sabel MS et al. RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. Breast Cancer Res. Treat.93(2), 101–110 (2005).
   PubMed Web of Science ®Google Scholar
• Kleer CG, Zhang Y, Pan Q et al.WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene21(20), 3172–3180 (2002).
   PubMed Web of Science ®Google Scholar
• Kleer CG, Zhang Y, Pan Q et al.WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res. Treat.6(2), 110–115 (2004).
   Google Scholar
• Van Laere S, Van der Auwera I, Van den Eynden GG et al. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res. Treat.93(3), 237–246 (2005).
   PubMedGoogle Scholar
• Bertucci F, Finetti P, Rougemont J et al. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res.64(23), 8558–8565 (2004).
   PubMed Web of Science ®Google Scholar
• Bertucci F, Finetti P, Rougemont J et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res.65(6), 2170–2178 (2005).
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA98(19), 10869–10874 (2001).
   PubMed Web of Science ®Google Scholar
• Van Laere SJ, Van den Eynden GG, Van der Auwera I et al. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res. Treat.95(3), 243–255 (2006).
   PubMed Web of Science ®Google Scholar
• Van Laere S, Van der Auwera I, Van den Eynden G et al. Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis. Br. J. Cancer97(8), 1165–1174 (2007).
   Google Scholar
• Zhang X, Lin M, van Golen KI, Yoshioka K et al. Multiple signaling pathways are activated during insulin-like growth factor-I (IGF-1) stimulated breast cancer cell migration. Breast Cancer Res. Treat.93(2), 159–168 (2005).
   PubMed Web of Science ®Google Scholar
• Günhan-Bilgen I, Ustün EE, Memis A. Inflammatory breast carcinoma: mammographic, ultrasonographic, clinical, and pathologic findings in 142 cases. Radiology223(3), 829–838 (2002).
   Web of Science ®Google Scholar
• Chow CK. Imaging in inflammatory breast carcinoma. Breast Dis.22, 45–54 (2005).
   Google Scholar
• Yang WT, Le-Petross HT, Macapinlac H et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res. Treat.109(3), 417–426 (2008).
   Google Scholar
• Rieber A, Brambs HJ, Gabelmann A et al. Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur. Radiol.12(7), 1711–1719 (2002).
   PubMed Web of Science ®Google Scholar
• Rosen EL, Blackwell KL, Baker JA et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am. J. Roentgenol.181(5), 1275–1282 (2003).
   PubMed Web of Science ®Google Scholar
• Thukral A, Thomasson DM, Chow CK et al. Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab – initial experience. Radiology244(3), 727–735 (2007).
   Google Scholar
• Kell MR, Morrow M. Surgical aspects of inflammatory breast cancer. Breast Dis.22, 67–73 (2005–2006).
   Google Scholar
• Barker JL, Nelson AJ, Montague ED. Inflammatory carcinoma of the breast. Radiology121(1), 173–176 (1976).
   PubMed Web of Science ®Google Scholar
• Zucali R, Uslenghi C, Kenda R, Bonadonna G. Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy. Cancer37(3), 1422–1431 (1976).
   PubMed Web of Science ®Google Scholar
• Kuerer HM, Newman LA, Smith TL et al. Clinical course of breast cancer patients with complete pathological primary tumor axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol.17(2), 460–469 (1999).
   PubMed Web of Science ®Google Scholar
• Dawood S, Gonzalez-Angulo AM, Peintinger F et al. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M.D Anderson experience. Cancer110(6), 1195–1200 (2007).
   PubMedGoogle Scholar
• Ueno NT, Buzdar AU, Singeltary SE et al. Combined modality treatment of inflammatory breast carcinoma: twenty years of experience at M.D Anderson Center. Cancer Chemother. Pharmacol.40(4), 321–329 (1997).
   PubMed Web of Science ®Google Scholar
• Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN et al. Disease-free and overall survival after pathological complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer106(5), 1000–1006 (2006).
   Google Scholar
• Early Breast Cancer Trialists’ Collaborative group: effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet365(9472), 1687–1717 (2005).
   PubMed Web of Science ®Google Scholar
• Baldini E, Gardin G, Evangelista G et al. Long-term results of combined-modality therapy for inflammatory breast cancer. Clin. Breast Cancer5(5), 358–363 (2004).
   Google Scholar
• Harris EE, Schultz D, Bertsch H et al. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int. J. Radiat. Oncol. Biol. Phys.55(5), 1200–1208 (2003).
   Web of Science ®Google Scholar
• Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU et al. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M.D Anderson Cancer Center experience. Clin. Breast Cancer4(6), 415–419 (2004).
   PubMedGoogle Scholar
• Low JA, Berman AW, Steinberg SM et al. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J. Clin. Oncol.22(20), 4067–4074 (2004).
   PubMed Web of Science ®Google Scholar
• Veyret C, Levy C, Chollet P et al. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant study group GETIS 02 trial. Cancer107(11), 2535–2544 (2006).
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med.353(16), 1659–1684 (2005).
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med.353(16), 1673–1684 (2005).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S et al. Human breast cancer: use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N. Engl. J. Med.344(11), 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• Buzdar AU, Ibrahim NK, Francis D et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth receptor 2-positive operable breast cancer. J. Clin. Oncol.23(16), 3676–3685 (2005).
   PubMed Web of Science ®Google Scholar
• Hurley J, Doliny P, Reis I et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-postive locally advanced breast cancer. J. Clin. Oncol.24(12), 1831–1838 (2006).
   PubMed Web of Science ®Google Scholar
• Van Pelt AE, Mohsin S, Elledge RM et al. Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin. Breast Cancer4(5), 348–353 (2003).
   PubMedGoogle Scholar
• Limentani SA, Brufsky AM, Erban JK et al. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. J. Clin. Oncol.25(10), 1232–1238 (2007).
   PubMedGoogle Scholar
• Burstein HJ, Harris LN, Gelman R et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J. Clin. Oncol.21(15), 46–53 (2003).
   PubMed Web of Science ®Google Scholar
• Gianni L, Eiermann W, Semiglazov V et al. Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial. Presented at: San Antonio Breast Cancer Conference. San Antonio, TX, USA 10–14 December (2008) (Abstract 31).
   Google Scholar
• Xia W, Mullin RJ, Keith BR et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene21(41), 6255–6263 (2002).
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med.355(26), 2733–2743 (2006).
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd, Hurwitz HI, Dees EC et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol.23(23), 5305–5313 (2005).
   PubMed Web of Science ®Google Scholar
• Spector NL, Blackwell K, Hurley J et al. EGF103009, a Phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): clinical activity and biologic predictors of response. J. Clin. Oncol.ASCO Annual Meeting Proceedings Part I.24(18S), 502 (2006) (Abstract 502).
   Web of Science ®Google Scholar
• Cristofanilli M, Boussen H, Baselga J et al. A Phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC). Breast Cancer Res. Treat.(2006) (Abstract 1).
   Google Scholar
• Somlo G, Frankel P, Chow W et al. Prognostic indictors and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J. Clin. Oncol.22(10), 1839–1848 (2004).
   Google Scholar
• Cheng YC, Rondon G, Yang Y et al. The use of high dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary breast cancer after primary surgery or neoadjuvant chemotherapy. Biol. Blood Marrow Transplant.10(11), 794–804 (2004).
   Google Scholar
• Veins P, Palangie T, Janvier M et al. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br. J. Cancer81(13), 449–456 (1999).
   Google Scholar
• Perez CA, Fields JN, Fracasso PM et al. Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma. Cancer74, 466–476 (1994).
   PubMed Web of Science ®Google Scholar
• Flemming RY, Asmar L, Buzdar AU et al. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann. Surg. Oncol.4(6), 452–461 (1997).
   Google Scholar
• Stearns V, Ewing CA, Slack R, Penannen MF et al. Sentinel lymphadenopathy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann. Surg. Oncol.9(3), 235–242 (2002).
   PubMed Web of Science ®Google Scholar
• Woodward WA, Buchholz TA. The role of locoregional therapy in inflammatory breast cancer. Semin. Oncol.35(1), 78–86 (2008).
   Google Scholar
• Liao Z, Strom EA, Buzdar AU et al. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. Int. J. Radiat. Oncol. Biol. Phys.47(5), 1191–2000 (2000).
   PubMedGoogle Scholar
• Stopeck A, Sheldon M, Vahedian M et al. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin. Cancer Res.8(9), 2798–2805 (2002).
   PubMed Web of Science ®Google Scholar
• Miller KD, Trigo JM, Wheeler C et al. A multicenter Phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin. Cancer Res.11(9), 3369–3376 (2005).
   PubMed Web of Science ®Google Scholar
• Miller KD, Chap LI, Holmes FA et al. Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol.25(4), 792–799 (2005).
   Google Scholar
• Cobleigh MA, Langmuir VK, Sledge GW et al. A Phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin. Oncol.30, 117–124 (2003).
   PubMed Web of Science ®Google Scholar
• Wedam SB, Low JA, Yang XC et al. Anti-angiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J. Clin. Oncol.24(5), 769–777 (2006).
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Hutson TE. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr. Oncol. Rep.9(2), 115–119 (2007).
   PubMedGoogle Scholar
• Jonston SR, Hickish T, Ellis P et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J. Clin. Oncol.21(13), 2492–2499 (2003)
   Google Scholar